Research Article

FAS and FASLG Genetic Variants and Risk for Second Primary Malignancy in Patients with Squamous Cell Carcinoma of the Head and Neck

Dapeng Lei1,4,5, Erich M. Sturgis1,2, Li-E Wang2, Zhensheng Liu2, Mark E. Zafereo3, Qingyi Wei2, and Guojun Li1,2

Abstract

Background: Single-nucleotide polymorphisms in the promoter region of the FAS and FASLG may alter the transcriptional activity of these genes. We therefore investigated the association between the FAS and FASLG polymorphisms and risk for second primary malignancy (SPM) after index squamous cell carcinoma of the head and neck (SCCHN).

Methods: We used log-rank test and Cox proportional hazard models to assess the association of the four single-nucleotide polymorphisms (FAS -1377 G > A, FAS -670 A > G, FASLG -844 C > T, and FASLG -124 A > G) with the SPM-free survival and SPM risk among 1,286 incident SCCHN patients.

Results: Compared with patients having the FAS -670 AA or the FASLG -844 CC genotypes, the patients having variant genotypes of FAS -670 AG/GG or FASLG -844 CT/TT genotypes had a significantly increased risk for SPM, respectively. A trend for significantly increased SPM risk with increasing number of risk genotypes of the four polymorphisms was observed in a dose-response manner. Moreover, the patients with three or four combined risk genotypes had an ~1.8- or 2.5-fold increased risk for developing SPM compared with patients with zero or one risk genotypes, respectively.

Conclusions: Our results suggest a modestly increased risk for SPM after index SCCHN with FAS -670 A > G and FASLG -844 C > T polymorphisms and an even greater risk for SPM with multiple combined FAS and FASLG risk genotypes.

Impact: The FAS and FASLG polymorphisms may serve as a susceptible marker for SCCHN patients at high SPM risk. Cancer Epidemiol Biomarkers Prev; 19(6): 1484-91. ©2010 AACR.

Introduction

The incidence of squamous cell carcinoma of the head and neck (SCCHN) in the United States has been in decline over the past two decades, largely because of a decline in the prevalence of smoking (1). The poor prognosis for SCCHN patients has not significantly improved, partly because of the high frequency of second primary malignancies (SPM), which occurs in ~15% of SCCHN patients (2-4), although the diagnostic and therapeutic approaches for SCCHN patients have been improved.

Although previous and continued exposures to smoking and alcohol use are associated with risk for developing SPMs (5-7), only a small proportion of exposed individuals develops SPM, suggesting that genetic factors may contribute to the interindividual variation in susceptibility to SPMs (8-10). We and others (11-16) have reported that genetic predisposition involved in several molecular pathways, such as carcinogen metabolism, DNA repair, and cell cycle control, is associated with the risk for SPM after primary SCCHN.

Apoptosis is the physiologic mechanism of programmed cell death that plays an important role in diverse biological processes such as development, homeostasis of tissues, and elimination of cancer cells (17, 18). The acquired ability to resist apoptotic stimuli is one of the primary characteristics of a malignant cell, and abnormal regulation of apoptosis is a key mechanism in the development of cancer (19). FAS is a cell surface receptor that can interact with the FAS ligand (FASLG) to trigger apoptosis (20-22). Therefore, the FAS/FASLG pathway plays an important role in regulation of apoptosis and maintenance of cellular homeostasis, and genetic alteration of the FAS/FASLG signaling pathway may result in immune escape and, thus, tumorigenesis, including SPM.

Existing data suggest that polymorphisms of FAS/ FASLG have been associated with increased susceptibility to a variety of cancers, including SCCHN (23-30).
Single-nucleotide polymorphisms are the most common form of human genetic variation, and the functional single-nucleotide polymorphisms in the promoters of \textit{FAS} and \textit{FASLG} genes have been identified to be related to the differential expression of these two genes (31-33), which may affect risk for SPM after index SCCHN. For example, the \textit{FAS} -1377 G > A and -670 A > G polymorphisms have been shown to interfere with the specificity protein 1 and signal transducers and activators of transcription 1 transcription factor binding sites, respectively; hence decreasing promoter activity and, in turn, \textit{FAS} gene expression (31, 32), whereas the C allele of the \textit{FASLG} -844 C > T polymorphism creates a binding site for the CAAT/enhancer binding protein \( \beta \) transcription factor, resulting in higher basal expression of the \textit{FASLG} gene (33). However, there is no report on the functional relevance of the \textit{FASLG} -124 A > G polymorphism. Our previous study showed that the \textit{FAS} -670 A > G and -1377 G > A polymorphisms were associated with an increased risk for SCCHN (30), but no risk for SCCHN was associated with the \textit{FASLG} -844 C > T and -124 A > G polymorphisms. To date, the association between the \textit{FAS} and \textit{FASLG} polymorphisms and risk for SPM after index SCCHN has not been reported.

Given the role of the \textit{FAS} and \textit{FASLG} genes in regulating cell death and abnormal expression of \textit{FAS} and/or \textit{FASLG} in various types of tumors, including SCCHN, we hypothesized that \textit{FAS} and \textit{FASLG} polymorphisms contribute to genetic susceptibility to SPMs after index SCCHN, and these polymorphisms may be genetic markers to identify high-risk subgroups of SCCHN patients who might benefit from management of alternative treatment and predictable patient outcome. To test the hypothesis, we compared the SPM-free survival and the risk for SPM between the different genotyping groups in a cohort of 1,286 incident SCCHN patients.

\section*{Materials and Methods}

\subsection*{Study subjects}

Between May 1995 and January 2007, 1,667 patients with incident SCCHN were consecutively recruited at the University of Texas M.D. Anderson Cancer Center as part of an ongoing molecular epidemiologic study on SCCHN. These patients were newly diagnosed, histopathologically confirmed, and untreated squamous cell carcinomas of the oral cavity, oropharynx, hypopharynx, or larynx. All patients completed an Institutional Review Board-approved informed consent, without the restriction of age, sex, ethnicity, or clinical stage. Approximately 95\% of contacted patients consented to enrollment in the study. The exclusion criteria included any previous cancer history excepting nonmelanoma skin cancer, distant metastases at presentation, primary sinonasal tumors, salivary gland tumors, cervical metastases of unknown origin, and tumors outside the upper aerodigestive tract. In addition, blood samples for genotyping data were not available for some patients recruited early in the study, and these patients were excluded from this analysis, as were patients without follow-up and patients who underwent only palliative treatment. Therefore, there are a total of 1,286 patients available for the final analysis of this study.

Patients were monitored through their treatment and posttreatment course with regularly scheduled clinical and radiographic examinations. SPMs were distinguished from local recurrences based on modified criteria of Warren and Gates (34). Second lesions with different histopathologic type and/or occurring >5 years following treatment for the primary tumor and/or clearly separated by normal epithelium based on clinical and radiographic assessment were considered SPM. The second lesion was classified as a local recurrence rather than a SPM if there was discrepancy or differing opinion about the origin of the tumor. Pulmonary lesions were considered SPM if they had a nonsquamous histology or if they were isolated squamous lesions >5 years from initial SCCHN and felt to be SPM by the thoracic oncologist and thoracic surgeon. SPMs were then classified as tobacco-associated (e.g., SCCHN or cancers of the esophagus, lung, or bladder) and non-tobacco-associated SPM.

At presentation, all patients provided epidemiologic data, including alcohol and smoking status. Those subjects who had smoked at least 100 cigarettes in their lifetime were defined as ever smokers; otherwise, they were considered never smokers. Subjects who had drunk at least one alcoholic beverage per day for at least 1 year during their lifetime were defined as ever drinkers, and those who never had such a pattern of drinking were defined as never drinkers. Clinical data were obtained at initial presentation and through follow-up examinations and included overall stage at presentation of index tumor, site of index tumor, and treatment. Index cancer stage was then dichotomized into the early stage (including I and II clinical stage) and late stage (III and IV). We also grouped treatment into four categories: surgery only, surgery with radiotherapy and/or chemotherapy, radiotherapy, and radiotherapy plus chemotherapy.

\subsection*{Genotyping of the \textit{FAS} and \textit{FASLG} polymorphisms}

DNA was extracted from 1 mL of blood sample with the Qiagen DNA Blood Mini Kit (Qiagen) according to manufacturer's instructions. We genotyped the four single-nucleotide polymorphisms of the \textit{FAS} and \textit{FASLG} gene, \textit{FAS} -1377 G > A, \textit{FAS} -670 A > G, \textit{FASLG} -844 C > T, and \textit{FASLG} -124 A > G, by the PCR-RFLP assay (30). The primers, PCR and restriction enzymes for these polymorphisms have been described previously (30). Approximately 10\% of samples have been reassayed, showing 100\% concordance.

\subsection*{Statistical analysis}

For all analyses in this study, statistical significance was set at \( P < 0.05 \), and all tests were two sided. The Statistical Analysis System software (version 9.1.3; SAS Institute) was used to do all statistical analyses. SPM
occurrence was considered as the primary endpoint of the study. Student’s t test was used to compare the mean age and follow-up time of the patients who developed a SPM and those who did not. The differences in ethnicity, sex, smoking and alcohol status, index tumor site, index tumor stage, treatment, and genotype distributions between the two groups were evaluated using the χ² test. Time-to-event was calculated from the date of diagnosis of the index SCCHN to the date of SPM occurrence. Patients who were not known to have an event at the date of last contact or who died were censored. The associations between individual epidemiologic risk factors; clinical characteristics, including index tumor site, index tumor stage, and treatment variables; and time to the occurrence of SPMs were initially assessed using univariate Cox proportional hazards regression models. The data were consistent with the assumptions of the Cox proportional hazards regression model from the examination of Kaplan-Meier survival curves and log-minus-log survival plots.

In the univariate analysis, we evaluated epidemiologic variables, assessed at the time of diagnosis (such as age in years, ethnicity, sex, and smoking and alcohol status), and clinical characteristics (such as index tumor site, index tumor stage, and treatment). We did not incorporate any interaction terms in the first step in building a multivariable model for time to SPM occurrence. A multivariable proportional hazards model was built using the variables that had prognostic potential suggested by the univariate analysis (P < 0.25). Because of epidemiologic and clinical considerations in building the model, age, sex, and ethnicity were always retained in the main-effects and final multivariable model. We used a stepwise search strategy to build the multivariable models, for which a threshold level of 0.25 for the likelihood ratio test was used as a cutoff to determine whether a variable could be entered into or removed from the regression model. We assessed associations using hazard ratios and their 95% confidence intervals (95% CI) for an SPM development. The final fully adjusted Cox regression models included age, sex, ethnicity, and smoking and alcohol status.

Results

Patient characteristics

Table 1 shows the demographics, risk exposure, and clinical variables for the 1,286 patients, which included 1,166 patients who did not develop SPM and 120 (9.3%) patients who developed SPM. The overall median follow-up time was 29.7 months (range, 0-142.4 mo).

Of the 120 patients with SPM, 81 patients developed SPMs at tobacco-associated sites, including 44 (36.7%) SCCHN and 37 (30.8%) other tobacco-associated cancers (34, 28.3% lung cancer; 2, 1.7% esophageal cancer; 1, 0.83% bladder cancer); 35 (29.2%) developed SPMs at other sites (10, 8.3% prostate cancer; 8, 6.7% papillary thyroid carcinoma; 4, 3.3% colon adenocarcinoma; 3, 2.5% lymphoma; 3, 2.5% hepatic adenocarcinoma; 2, 1.7% breast cancer; 1, 0.83% each for the remainder, including sarcoma, renal cell carcinoma, endometrial carcinoma, leukemia, and maxillary sinus adenocarcinoma); and 4 (3.3%) developed SPMs at both sites (2, 1.7% patients with both SCCHN and prostate cancer; 2, 1.7% patients with both SCCHN and papillary thyroid carcinoma). Of the 44 patients with second SCCHN, 24 (55%) were synchronous SCCHN primaries. Of these 24 patients with synchronous SCCHN, two patients had bilateral oral cavity cancers, three had bilateral oropharyngeal cancers, one had bilateral hypopharyngeal cancers, and the remainder had simultaneous cancers of more than one head and neck subsite.

The mean age at diagnosis for the total patients was 57.5 years (range, 18-94 y; median, 57 y), and the mean age of patients at index SCCHN who developed SPM was significantly older compared with the mean age of patients who did not develop SPM (60.8 versus 57.1 y, respectively; P < 0.0001). Compared with the SPM-free group, patients who developed SPM were more likely older (P < 0.0001) and non-Hispanic Whites (P = 0.050). However, no significant differences were observed between patients who did not develop SPM and patients who developed SPM with regard to sex (P = 0.525), smoking (P = 0.129), alcohol drinking (P = 0.352), index cancer site (P = 0.322), index cancer stage (P = 0.681), and treatment (P = 0.889).

Association between the FAS and FASLG polymorphisms and risk for SPM

As shown in Table 2, FAS -670 AG + GG genotypes were more frequent in the patients who developed SPM (83.3%) than in the patients who did not develop SPM (73.2%) and were associated with a significantly increased risk for SPM compared with the FAS -670 AA genotype (odds ratio, 1.57; 95% CI, 1.00-2.54). Compared with the FASLG -844 CC genotype, the FASLG -844 CT + TT genotypes were also more frequent in the patients who developed SPM (70.8%) than in the patients who did not develop SPM (59.2%) and were associated with a significantly increased risk for SPM (odds ratio, 1.71; 95% CI, 1.15-2.54). However, the differences between the variant genotypes (FAS -1377 GA + AA or FASLG -124 AG + GG) and the wild-type homozygous genotypes (FAS -1377 GG or FASLG -124 AA) for FAS -1377 G > A or FASLG -124 A > G polymorphism were not statistically significant (P = 0.879 and 0.458, respectively). For these two polymorphisms, no significant SPM risks were observed between the patients who developed SPM and who did not develop SPM (odds ratio, 0.87; 95% CI, 0.56-1.36 for FAS -1377 G > A; odds ratio, 1.15; 95% CI, 0.75-1.77 for FASLG -124 A > G).

Association between the combined genotypes of the FAS and FASLG polymorphisms and SPM risk

Because any of the four single-nucleotide polymorphisms of the FAS and FASLG genes in the apoptotic
pathway seemed to have a minor effect on risk for SPM, we then did a combined analysis of all four single-nucleotide polymorphisms to focus on potentially modifying effect of the combined genotypes on risk for SPM (Table 3). In the 1,286 patients who had data available on all four single-nucleotide polymorphisms, we categorized all putative risk (odds ratio, >1.0) genotypes of each single-nucleotide polymorphism into a new variable according to the number of risk genotypes (for the protective genotype, e.g., FAS-1377 G > A, we reversed the reference group). For the combined analysis, we found that the patients with 0 to 2 risk genotypes of the four polymorphisms experienced a significantly reduced SPM-free survival compared with patients with 3 to 4 risk genotypes (log-rank, $P = 0.0143$; Fig. 1). There was a trend for increased SPM risk with increasing number of risk genotypes, and this trend in risk was statistically significant in a dose-response manner ($P = 0.004$ for trend).

### Discussion

In this study, we investigated the association between the FAS-1377 G > A and -670A > G and the FASLG-844 C > T and FASLG-124 A > G polymorphisms on the risk for SPM after index SCCHN. We found that FAS -670 A > G and FASLG -844 C > T polymorphisms were associated with a significantly increased risk for developing SPM in patients with SCCHN. Although we did not observe any significant association of FAS-1377 G > A or FASLG-124 A > G polymorphism with risk for SPM, we did observe an effect of the combined risk genotypes of the four polymorphisms specifically, the patients with 3 or 4 risk genotypes had an ~1.8- (hazard ratio, 1.83; 95% CI, 1.00-3.36) or 2.5-fold (hazard ratio, 2.53; 95% CI, 1.26-5.06) increased risk for developing SPM compared with patients with 0 to 1 risk genotypes, respectively.
on SPM risk in patients with primary SCCHN, and the trend in risk was statistically significant in a dose-response manner. In addition, the patients with 3 or 4 risk genotypes had almost 1.8- or 2.5-fold increased risk for developing SPM compared with patients with 0 or 1 risk genotypes. To the best of our knowledge, there have been no previous studies examining the combined effects of genetic variants in the apoptotic pathway on risk for SPM after index SCCHN.

It has been shown that downregulation of FAS may protect tumor cells from elimination by antitumor immune responses, whereas upregulation of FASLG may increase the ability of tumor cells to counterattack the immune system by inducing apoptosis of FAS-sensitive lymphocytes (35-38). Alteration of FAS and FASLG expression decrease the apoptotic capacity of cells, and many tumor cells might evade or suppress the immune system. Most studies indicated that decreasing the expression of FAS and/or increasing the expression of FASLG is a common feature of malignant transformation and an early event associated with the development of most human cancers, including SCCHN (23-27, 30, 39-41). Given the important roles of FAS and FASLG in apoptosis process, it is biologically plausible that alteration of FAS and FASLG genes, such as genetic polymorphisms, may affect risk for cancer, including SPM.

The FAS -1377 G > A polymorphism has been reported to be associated with increased risk for developing lung

### Table 2. SPM risk associated with FAS and FASLG polymorphisms after index SCCHN

<table>
<thead>
<tr>
<th>Genotypes</th>
<th>Total (N = 1,286)</th>
<th>SPM-free (n = 1,166)</th>
<th>SPM (n = 120)</th>
<th>P*</th>
<th>HR (95% CI)†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>%</td>
<td>n</td>
<td>%</td>
<td>n</td>
</tr>
<tr>
<td>FAS -1377 G &gt; A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GG (ref)</td>
<td>1,023</td>
<td>79.6</td>
<td>927</td>
<td>79.5</td>
<td>96</td>
</tr>
<tr>
<td>GA + AA</td>
<td>263</td>
<td>20.4</td>
<td>239</td>
<td>20.5</td>
<td>24</td>
</tr>
<tr>
<td>FAS -670 A &gt; G</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AA (ref)</td>
<td>333</td>
<td>25.9</td>
<td>313</td>
<td>26.8</td>
<td>20</td>
</tr>
<tr>
<td>AG + GG</td>
<td>953</td>
<td>74.1</td>
<td>853</td>
<td>73.2</td>
<td>100</td>
</tr>
<tr>
<td>FASLG -844 C &gt; T</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC (ref)</td>
<td>511</td>
<td>39.7</td>
<td>476</td>
<td>40.8</td>
<td>35</td>
</tr>
<tr>
<td>CT + TT</td>
<td>775</td>
<td>60.3</td>
<td>690</td>
<td>59.2</td>
<td>85</td>
</tr>
<tr>
<td>FASLG -124 A &gt; G</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AA (ref)</td>
<td>981</td>
<td>76.3</td>
<td>889</td>
<td>76.2</td>
<td>92</td>
</tr>
<tr>
<td>AG + GG</td>
<td>305</td>
<td>23.7</td>
<td>277</td>
<td>23.8</td>
<td>28</td>
</tr>
</tbody>
</table>

Abbreviations: HR, hazard ratio; ref, reference group.
*χ² Test for differences in the distribution of FAS and FASLG genotypes between the patients who developed SPM and the patients who did not.
†Adjusted for age, sex, ethnicity, tobacco smoking, and alcohol drinking in a Cox model.

### Table 3. SPM risk associated with FAS and FASLG polymorphisms after index SCCHN

<table>
<thead>
<tr>
<th>No. risk genotypes</th>
<th>Total (N = 1,286)</th>
<th>SPM-free (n = 1,166)</th>
<th>SPM (n = 120)</th>
<th>P*</th>
<th>HR (95% CI)†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>%</td>
<td>n</td>
<td>%</td>
<td>n</td>
</tr>
<tr>
<td>0-1 (ref)</td>
<td>235</td>
<td>18.3</td>
<td>221</td>
<td>19.0</td>
<td>14</td>
</tr>
<tr>
<td>2</td>
<td>480</td>
<td>37.3</td>
<td>438</td>
<td>37.6</td>
<td>42</td>
</tr>
<tr>
<td>3</td>
<td>420</td>
<td>32.7</td>
<td>375</td>
<td>32.1</td>
<td>45</td>
</tr>
<tr>
<td>4</td>
<td>151</td>
<td>11.7</td>
<td>132</td>
<td>11.3</td>
<td>19</td>
</tr>
<tr>
<td>Trend</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*χ² test for differences in the distribution of combined genotypes between the patients who developed SPM and the patients who did not.
†Adjusted for age, sex, ethnicity, tobacco smoking and alcohol drinking in a Cox model.
cancer (24), breast cancer (25, 39), esophageal squamous cell cancer (26), colorectal cancer (27), SCCHN (30), and acute myeloid leukemia (32). FAS -670 A > G polymorphism was found to be associated with increased risk for esophageal squamous cell cancer (26), SCCHN (30), and gynecologic cancer (40). In the current study, we observed the significant association of FAS -670 A > G but not FAS -1377 G > A polymorphism with risk for SPM after index SCCHN. Although the exact mechanism of how the polymorphism affect SPM development is unclear, Sibley et al. (32) reported that the FAS -670 G allele had a greatly reduced ability to bind transcription factor signal transducers and activators of transcription 1 and less expressed on ex vivo-stimulated T cells (41). Decreased FAS expression resulting from a FAS promoter polymorphism may help the transformed cells evade FAS-mediated cell death, subsequently affecting risk for cancer, including SPM.

The FASLG -844 T/C polymorphism is also located in the promoter region of the gene, and basal FASLG expression is higher in cells carrying the C allele than in cells carrying the T allele as measured in a luciferase reporter assay and when expressed in peripheral blood fibrocytes (33). Sun et al. (41) found that FASLG -844 C allele is associated with increased activation-induced T cell apoptosis in vitro, which is consistent with the findings in current study (25). Transformed cells with the FASLG -844 CC genotype that express a high level of FASLG may create an immunoprivileged site by killing cytotoxic immune cells and thus escape host immunosurveillance. The association between the FASLG -844 C > T polymorphism and increased risk for some cancers has been reported in previous studies (24-27, 33, 41). In this study, we found that the FASLG -844 variant genotypes (CT + TT) were associated with a significantly increased risk for SPM in patients after index SCCHN compared with the FASLG -844 CC genotype, although our previous case-control study indicated that no risk for SCCHN was associated with any of the FASLG genotypes (30). The exact mechanism for these conflicting results remains unknown. It might be possible that the effect of this FASLG -844 C > T polymorphism in normal epithelium of the head and neck differs from those in SCCHN tumor tissues, which have numerous somatic changes. It also might be that this FASLG -844 C > T polymorphism may function differently in etiology (case-control study) and prognosis (case only study) because the normal epithelium of the head and neck and SCCHN tumor tissues have significant differences in genetic profiles such as somatic genetic changes. Moreover, this polymorphism of FASLG -844 C > T may have different roles in etiology and prognosis through the interaction of this FASLG -844 C > T variant with the normal genes in normal tissues, genetically altered genes in SCCHN tissues, smoking behavior, human papillomavirus (HPV), and other environmental risk factors. Several studies have also suggested that genetic factors and previous treatments, within the context of previous or continued exposure to risk factors, may affect the risk for SPM after index SCCHN (42-44). Therefore, all these factors may affect functionality of this FASLG -844 C > T polymorphism in the development of SPM and SCCHN. However, these hypotheses need to be tested in future studies.

Although this was a large and well-characterized cohort in SCCHN patients by Head and Neck Center at M.D. Anderson Cancer Center, there were several
inherent limitations in our study. Firstly, multiple ethnicities were included in this cohort, in which 84.5% of patients were non-Hispanic Whites. Secondly, the demographics, exposure, and clinical data for the cohort were collected prospectively, whereas clinical outcomes, including SPM, were collected retrospectively without a strictly defined screening or follow-up regimen. Furthermore, the follow-up time to the development of SPM in this study may have been limited by patients with stage III and IV index cancer who were lost to follow-up. These patients may not have had as much opportunity to develop SPM because of being recruited lately or dying relatively soon after diagnosis. It is also possible that a screening bias in the detection of SPMs exists, such that tobacco-associated SPMs (that is, SCCHN, esophageal, or lung cancers) were detected more readily than non-tobacco-associated cancers. However, such a bias should be nondirectional (that is, not different between groups having different genotypes). In addition, the low SPM rate may be due to our high prevalence of never smokers (26.7%) and our strict criteria in defining SPM. Finally, the absence of HPV status did not allow us to evaluate its potential influence on the development of SPMs in patients with index SCCHN. With the information available, we will take HPV and smoking status into account as confounders in our future studies when we analyze the associations between this and/or other genetic polymorphisms and risk for SPM. Despite these limitations, the current investigation supports a significant role of FAS and FASLG polymorphisms in individual variation in susceptibility to SPM after index SCCHN.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Margaret Lung, Angeli Fairley, Liliana Mugartegui, and Kathryn Tipton with assistance with patient recruitment.

Grant Support

Research Training Award; The American Laryngological, Rhinologic, and Otological Society (E.M. Sturgis); University of Texas M.D. Anderson Cancer Center Start-up Funds (E.M. Sturgis); National Institute of Environmental Health Sciences grant RO1 ES-11740 (Q. Wei); and NIH grants P30 CA-16672 (The University of Texas M.D. Anderson Cancer Center), and NIH CA135679 (G. Li), and CA133099 (G. Li).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 01/11/2010; revised 03/23/2010; accepted 03/29/2010; published OnlineFirst 05/25/2010.

References


FAS and FASLG Polymorphisms and Second Primary Malignancies


FAS and FASLG Genetic Variants and Risk for Second Primary Malignancy in Patients with Squamous Cell Carcinoma of the Head and Neck

Dapeng Lei, Erich M. Sturgis, Li-E Wang, et al.


Updated version  Access the most recent version of this article at: doi:10.1158/1055-9965.EPI-10-0030

This article cites 44 articles, 12 of which you can access for free at: http://cebp.aacrjournals.org/content/19/6/1484.full#ref-list-1

This article has been cited by 3 HighWire-hosted articles. Access the articles at: http://cebp.aacrjournals.org/content/19/6/1484.full#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.